ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23%
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ESSA Pharma Inc
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Accounts Receivables
$163k
CAGR 3-Years
-31%
CAGR 5-Years
-16%
CAGR 10-Years
5%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Accounts Receivables
$10.3m
CAGR 3-Years
-8%
CAGR 5-Years
-2%
CAGR 10-Years
59%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Accounts Receivables
$36.5m
CAGR 3-Years
55%
CAGR 5-Years
136%
CAGR 10-Years
80%
Covalon Technologies Ltd
XTSX:COV
Accounts Receivables
CA$6.1m
CAGR 3-Years
2%
CAGR 5-Years
-3%
CAGR 10-Years
20%
Spectral Medical Inc
TSX:EDT
Accounts Receivables
CA$337k
CAGR 3-Years
-16%
CAGR 5-Years
2%
CAGR 10-Years
-6%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.8 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Accounts Receivables?
Accounts Receivables
163k USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Accounts Receivables amounts to 163k USD.

What is ESSA Pharma Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
5%

Over the last year, the Accounts Receivables growth was 21%. The average annual Accounts Receivables growth rates for ESSA Pharma Inc have been -31% over the past three years , -16% over the past five years , and 5% over the past ten years .

Back to Top